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INTRODUCTION:
A major challenge in treatment of advanced prostate cancer is the development of castration-resistant prostate cancer after androgen deprivation therapy (1) . Despite the depletion of circulating androgens, androgen receptor (AR) signaling remains active in the tumors, constituting a major mechanism of castration-resistant progression (1) . Recently, accumulating evidence points to the important contribution of constitutively-active, ligand-binding-domain-truncated AR splice variants (AR-Vs) to castration resistance (2) (3) (4) (5) (6) . AR-Vs have been shown to regulate the expression of both canonical AR targets and a unique set of targets enriched for cell-cycle function (3, 5, 7) . The full-length AR (AR-FL) needs to dimerize to regulate target-gene expression (8) , but little is known about AR-V dimerization. The purpose of this study is to define the dimeric nature of AR-Vs. The bimolecular fluorescence complementation (BiFC) assay and the bioluminescence resonance energy transfer (BRET) assay were used to address this issue.
BODY: Task 1.
To generate BRET-and BiFC-fusion constructs of AR v567es , AR-V7, and AR-FL and to functionally validate the fusion proteins.
BiFC-fusion constructs: AR
v567es and AR-V7 are two major AR-Vs expressed in castration-resistant prostate cancer specimens, and high expression has been correlated with short survival of the patients (9) . To generate different BiFC-fusion constructs of AR-FL, AR v567es , and AR-V7, we PCR amplified human AR-FL, AR v567es , and AR-V7 cDNAs from their respective expression constructs, and cloned the PCR amplicons separately into a TA-cloning vector. Fusion constructs of AR-FL, AR v567es , and AR-V7 with either the N-or Cterminal fragment of the Venus fluorescent protein (VN-or VC-VFP) were then generated by subcloning the cDNAs from the TA-vectors into the SalI and XhoI sites of the pBiFC-VN155 and pBiFC-VC155 vectors (kindly provided by Dr. Chang-Deng Hu at Purdue University). To delineate the dimerization interface, we generated mutant BiFC-AR-V constructs with mutation at the FxxLF motif (F23,27A/L26A) and/or D-box (A596T/S597T), which mediate AR-FL homodimerization through N/C-terminal interaction or DNA-binding domain (DBD)/DBD interaction, respectively (8) . The mutant constructs were generated by site-directed mutagenesis by using the Q5 site-Directed Mutagenesis Kit (New England BioLabs). Each fusion construct was transiently transfected into the AR-null PC-3 cell line, and the expression of the fusion proteins confirmed by Western blot analyses (Fig. 1) . The ability of the wild-type fusion proteins to trans-activate was validated by luciferase assay with the co-transfection of an androgen-responsive element (ARE)-luciferase reporter plasmid containing three ARE regions ligated in tandem to the luciferase reporter, ARR3-luc (Fig. 2) . BRET-fusion constructs: Different BRET-fusion constructs of AR-FL, AR v567es , and AR-V7 were generated by subcloning the AR-FL, AR v567es , and AR-V7 cDNA from the respective TA-vectors into the BamHI and XbaI sites of the RLuc8.6 luciferase construct and the TurboFP635 construct (10) (kindly provided by Dr. Sanjiv Gambhir at Stanford University). Each fusion construct was then transiently transfected into PC-3 cells, and the expression of the fusion proteins confirmed by Western blot analyses (Fig. 3) . The ability of the fusion proteins to regulate target gene expression was validated by qRT-PCR analysis of prostatespecific antigen (PSA) levels (Fig. 4) .
Task 2.
To delineate dimer formation among AR v567es , AR-V7, and AR-FL, and response to androgen and anti-androgen.
BiFC detection of AR-V/AR-FL heterodimerization:
For BiFC detection of AR-V/AR-FL dimerization, we co-transfected the AR-V-and AR-FL BiFC fusion proteins into PC-3 cells. The principle of the BiFC assay is that if two ARs dimerize, the interaction can re-generate the Venus fluorescent protein to emit fluorescent signal (11) . We found that both AR-V7 and AR v567es dimerize with AR-FL, and that the dimerization does not require androgen (Fig. 5) . Only mutating both the FxxLF motif and the D-Box abolished AR-FL/AR-V dimerization, indicating that both N/C and DBD/DBD interactions mediate the dimerization. Mutating one motif did not lead to significant change of BiFC signal is possibly due to compensation of the loss of one mode of interaction by the other. Similar result was obtained in DU145 cells (Fig. 6) . Intriguingly, although AR-FL/AR v567es dimerization was observed in both the cytoplasm and nucleus, AR-FL/AR-V7 dimerization was detected primarily in the nucleus. On the other hand, we found that, similar to AR v567es (5), AR-V7 induces AR-FL nuclear entry (Fig. 7) , indicating their initial interaction in the cytoplasm. Thus, the inability to detect cytoplasmic dimerization is likely because VFP re-generation from the VN and VC fragments is slower than AR-V7/AR-FL nuclear translocation. Of note, immunofluorescence assay was used to make sure the protein fusion did not alter the subcellular localizations of the AR isoform (Fig. 8) . Moreover, we showed that pretreatment of cells with dihydrotestosterone (DHT) attenuated AR-V7/AR-FL heterodimerization, and this effect was blocked by the antiandrogen MDV3100 (Fig. 9) , indicating potential competition of AR-V with AR-FL for dimerizing with AR-FL. 
BiFC detection of AR-V/AR-V dimerization:
We further found that, like liganded AR-FL (Fig. 10A) , both AR-Vs can also form a homodimer ( Fig. 10B and 10C; Fig. 11 ). Moreover, AR-V7 and AR v567es can also heterodimerize (Fig. 10D) . Mutating the D-box, but not the FxxLF motif, abolished the interactions, indicating that AR-Vs homodimerize and heterodimerize with each other through DBD/DBD interaction. We also generated pBiFC-CN155 and pBiFC-CC155 fusion constructs of AR-V7 and AR v567es for the purpose of confirming the competition of AR-V with AR-FL for dimerizing with AR-FL by using the BiFC protocol of simultaneous visualization of multiple protein interactions. Unfortunately, we still have technical difficulty of getting the assay to work. We therefore decide to use BRET assay in the future to further demonstrate the competition. 
BRET confirmation of AR-V/AR-FL and AR-V/AR-V dimerization:
BRET is based on energy transfer between a luciferase energy donor and a fluorescent protein energy acceptor when the donor and acceptor are brought into close proximity by their fused proteins (10) . Different combinations of the fusion proteins were tested in PC-3 cells. Fig. 12 is the saturation curve for different combinations, showing BRET ratios increase hyperbolically and rapidly saturate, indicating specific protein-protein interaction (12) . Thus, the BRET data confirmed the BiFC results, showing the ability of AR-V to homodimerize and to heterodimerize with AR-FL and another AR-V. We are in the process of characterizing the effect of androgen and anti-androgen MDV3100 on AR-V/AR-FL dimerization by the BRET assay. 
Dimerization is required for transactivation:
We co-transfected the wild-type or the dimerization mutants of AR-V with the ARR3-luc construct into PC-3 cells, and found that the dimerization mutants completely lost the ability to trans-activate (Fig. 13) , indicating an absolute requirement of dimerization for AR-V transactivation.
KEY RESEARCH ACCOMPLISHMENTS:
 We showed that AR-V can form a heterodimer with AR-FL through N/C and DBD/DBD interactions, and the dimerization does not require androgen.
 We showed that AR-V can homodimerize or dimerize with another AR-V through DBD/DBD interaction, and the dimerization does not require androgen.
 We identified the dimerization interface.
 We showed that, similar to AR v567es , AR-V7 can induce AR-FL nuclear translocation.
 We showed potential competition of AR-V with AR-FL for dimerizing with AR-FL.
 We showed that dimerization is required for AR-V transactivation.
REPORTABLE OUTCOMES:
 TurboFP-AR-FL/AR-V7-Rluc8.6 ratio Fig. 12 . BRET saturation curve. Indicated TurboFP and Rluc8.6 fusion constructs were co-transfected into PC-3 cells at different ratios, and BRET signal measured after addition of the coelenterazine substrate. Cells were cultured under androgendeprived condition unless specified. DHT, 1 nM for 24 hr. 
